in

Granules India Gets USFDA Nod For Capsules That Treat ADHD

The company said Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older.

Read More

What do you think?

Written by pulseadmin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

RBI files application for insolvency proceedings against Aviom India Housing Finance

JSW Group's Sajjan Jindal To Transform Gulmarg Into World-Class Holiday Destination